ePrivacy and GPDR Cookie Consent by TermsFeed Generator

BENDAMUSTINE GLENMARK

2,5MG/ML INF PLV CSL 5X25MG

Announcement of launch, break or close-out of marketing of a medicinal product
Type of announcement Effective date Alternate medicines ? Reason for interruption/cessation of marketing Estimated renewal date
Cessation of marketing 23.06.2022 0235078, 0235082, 0241291, 0241293
Commercial/marketing reasons
Resumption of marketing 18.01.2021
Interruption of marketing 07.12.2020 0235078, 0235082
Capacity/distribution reasons .
Placing on the market 06.06.2018

All reports are available in the Overview.

Back to list